Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
LAB Quote, Financials, Valuation and Earnings
Last price:
$1.48
Seasonality move
:
10.63%
Day range:
$1.42 - $1.51
52-week range:
$0.92 - $2.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.32x
P/B ratio:
1.41x
Volume:
750.2K
Avg. volume:
1.9M
1-year change:
-19.67%
Market cap:
$565.3M
Revenue:
$174.4M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$18M | -$0.02 | -60.4% | -72.53% | $1.65 |
|
ADGM
Adagio Medical Holdings, Inc.
|
-- | -$0.24 | -100% | -91.79% | $4.00 |
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
LNSR
LENSAR, Inc.
|
$17.8M | -$0.08 | 30.98% | -90.51% | $15.00 |
|
MOVE
Movano, Inc.
|
$3.4M | -$7.10 | 76.06% | -41.21% | $30.00 |
|
NPCE
NeuroPace, Inc.
|
$24.6M | -$0.19 | 13.69% | -5.76% | $19.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$1.47 | $1.65 | $565.3M | -- | $0.00 | 0% | 4.32x |
|
ADGM
Adagio Medical Holdings, Inc.
|
$1.06 | $4.00 | $22.3M | 218.00x | $0.00 | 0% | 118.08x |
|
INBS
Intelligent Bio Solutions, Inc.
|
$4.98 | -- | $4.8M | -- | $0.00 | 0% | 9.90x |
|
LNSR
LENSAR, Inc.
|
$12.01 | $15.00 | $143.5M | -- | $0.00 | 0% | 2.41x |
|
MOVE
Movano, Inc.
|
$7.97 | $30.00 | $6.7M | -- | $0.00 | 0% | 12.06x |
|
NPCE
NeuroPace, Inc.
|
$16.19 | $19.25 | $539.3M | -- | $0.00 | 0% | 5.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.589 | 5.49% | 1.93x |
|
ADGM
Adagio Medical Holdings, Inc.
|
106.35% | 2.155 | 73.62% | 0.48x |
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.804 | 21.48% | 0.47x |
|
LNSR
LENSAR, Inc.
|
-31.16% | -1.208 | 1.79% | 0.65x |
|
MOVE
Movano, Inc.
|
212.35% | 2.628 | 67.05% | 0.29x |
|
NPCE
NeuroPace, Inc.
|
79.36% | 0.212 | 20.74% | 3.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
ADGM
Adagio Medical Holdings, Inc.
|
-$531K | -$5.7M | -193.23% | -340.49% | -- | -$3.5M |
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
MOVE
Movano, Inc.
|
-$200K | -$2.6M | -337.24% | -410.28% | -3238.75% | -$1.6M |
|
NPCE
NeuroPace, Inc.
|
$21.2M | -$2.6M | -27.09% | -149.8% | -9.51% | -$2M |
Standard BioTools, Inc. vs. Competitors
-
Which has Higher Returns LAB or ADGM?
Adagio Medical Holdings, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of --. Standard BioTools, Inc.'s return on equity of -24.44% beat Adagio Medical Holdings, Inc.'s return on equity of -340.49%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M ADGMAdagio Medical Holdings, Inc.-- -$0.66 $20.7M -
What do Analysts Say About LAB or ADGM?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 5.44%. On the other hand Adagio Medical Holdings, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 300%. Given that Adagio Medical Holdings, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Adagio Medical Holdings, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 ADGMAdagio Medical Holdings, Inc.1 0 0 -
Is LAB or ADGM More Risky?
Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison Adagio Medical Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or ADGM?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Adagio Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or ADGM?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Adagio Medical Holdings, Inc. quarterly revenues of --. Standard BioTools, Inc.'s net income of -$31.7M is lower than Adagio Medical Holdings, Inc.'s net income of -$10.1M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Adagio Medical Holdings, Inc.'s PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.32x versus 118.08x for Adagio Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M ADGMAdagio Medical Holdings, Inc.118.08x 218.00x -- -$10.1M
-
Which has Higher Returns LAB or INBS?
Intelligent Bio Solutions, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -269.38%. Standard BioTools, Inc.'s return on equity of -24.44% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M -
What do Analysts Say About LAB or INBS?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 5.44%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 2309.64%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 INBSIntelligent Bio Solutions, Inc.0 0 0 -
Is LAB or INBS More Risky?
Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or INBS?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or INBS?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. Standard BioTools, Inc.'s net income of -$31.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.32x versus 9.90x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M INBSIntelligent Bio Solutions, Inc.9.90x -- $1.1M -$3M
-
Which has Higher Returns LAB or LNSR?
LENSAR, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -25.94%. Standard BioTools, Inc.'s return on equity of -24.44% beat LENSAR, Inc.'s return on equity of -1013.45%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M -
What do Analysts Say About LAB or LNSR?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 5.44%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 24.9%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 LNSRLENSAR, Inc.0 2 0 -
Is LAB or LNSR More Risky?
Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.
-
Which is a Better Dividend Stock LAB or LNSR?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or LNSR?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Standard BioTools, Inc.'s net income of -$31.7M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.32x versus 2.41x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M
-
Which has Higher Returns LAB or MOVE?
Movano, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -5036.25%. Standard BioTools, Inc.'s return on equity of -24.44% beat Movano, Inc.'s return on equity of -410.28%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M MOVEMovano, Inc.-250% -$4.73 $1.5M -
What do Analysts Say About LAB or MOVE?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 5.44%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3664.12%. Given that Movano, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Movano, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 MOVEMovano, Inc.0 0 0 -
Is LAB or MOVE More Risky?
Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or MOVE?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or MOVE?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Movano, Inc. quarterly revenues of $80K. Standard BioTools, Inc.'s net income of -$31.7M is lower than Movano, Inc.'s net income of -$4M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.32x versus 12.06x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M MOVEMovano, Inc.12.06x -- $80K -$4M
-
Which has Higher Returns LAB or NPCE?
NeuroPace, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -12.78%. Standard BioTools, Inc.'s return on equity of -24.44% beat NeuroPace, Inc.'s return on equity of -149.8%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M NPCENeuroPace, Inc.77.39% -$0.11 $89.7M -
What do Analysts Say About LAB or NPCE?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 5.44%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 18.9%. Given that NeuroPace, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe NeuroPace, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 NPCENeuroPace, Inc.7 0 0 -
Is LAB or NPCE More Risky?
Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or NPCE?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or NPCE?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. Standard BioTools, Inc.'s net income of -$31.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.32x versus 5.44x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M NPCENeuroPace, Inc.5.44x -- $27.4M -$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
